SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
Guggenheim SMID Cap Biotech Conference
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, February 5 at 10:30 a.m. ET | |
| Location: | New York, NY | |
| Webcast link: | /webcast/guggen2/register.aspx?conf=guggen2&page=gpcr&url=https://wsw.com/webcast/guggen2/gpcr/2003892 | |
Leerink Global Healthcare Conference
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Monday, March 10 at 1:00 p.m. ET | |
| Location: | Miami, FL | |
| Webcast link: | /webcast/leerink38/register.aspx?conf=leerink38&page=gpcr&url=https://wsw.com/webcast/leerink38/gpcr/2218364 | |
Jefferies Biotech on the Bay Summit
| Format: | 1x1 meetings | |
| Date: | Tuesday, March 11 | |
| Location: | Miami, FL |
The live and archived webcasts of the fireside chats will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$30.81 |
| Daily Change: | 0.26 0.85 |
| Daily Volume: | 798,451 |
| Market Cap: | US$1.770B |
August 06, 2025 May 08, 2025 February 27, 2025 December 17, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
